Asaduddin Aiman, Aisyah Farida, Indarto Dono, Mashuri Yusuf
Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Biomedical Laboratory, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
ARYA Atheroscler. 2022 Jun;18(6):2709. doi: 10.48305/arya.2022.11879.2709. Epub 2022 Dec 1.
HDL has been identified a s a p otential n ew t reatment f or atherosclerosis. Targeting lipid metabolism via the Reverse Cholesterol Transport (RCT) pathway can improve HDL metabolism. Apolipoprotein A-I mimetic peptides (ApoA-I MPs) are able to increase HDL metabolism. Thus, this systematic review aimed to examine the potential effect o f A poA-I M Ps a gainst a therosclerosis i n mice models through the RCT mechanism.
This systematic review was conducted using previous in vivo studies published in four scientific databases over the last ten years (PubMed, SCOPUS, ProQuest, and Science Direct) and was based on the Systematic Review Protocol for Animal Intervention Studies (SYRCLE) protocol.
This study's primary outcome was a reduction in atherosclerotic plaque, where 16 articles were qualified for this study. Based on the risk of bias analysis, these articles had a low risk of bias. Most in vivo studies (13 of 16) showed that ApoA-I MPs significantly reduced atherosclerotic plaque formation. Generally, ApoA-I MPs played an important role in regulating HDL metabolism (HDL remodeling process, increased cholesterol efflux, and stimulated RC T pathway) and an ti-inflammatory agent. Apo A-I MPs may differ in their ability to reduce atherosclerotic plaque depending on the peptide sequence and administration route.
ApoA-I MPs can reduce atherosclerotic plaque formation in mice by increasing cholesterol efflux vi a th e RC T pa thway. Fu rther in vestigation is re quired to su pport th e de velopment of ApoA-I MPs as a new therapy for atherosclerosis in humans.
高密度脂蛋白（HDL）已被确定为动脉粥样硬化的一种潜在新疗法。通过逆向胆固醇转运（RCT）途径靶向脂质代谢可改善HDL代谢。载脂蛋白A-I模拟肽（ApoA-I MPs）能够增加HDL代谢。因此，本系统评价旨在通过RCT机制研究ApoA-I MPs对小鼠模型中动脉粥样硬化的潜在作用。
本系统评价使用过去十年在四个科学数据库（PubMed、SCOPUS、ProQuest和ScienceDirect）上发表的先前体内研究进行，并基于动物干预研究系统评价方案（SYRCLE）方案。
本研究的主要结局是动脉粥样硬化斑块减少，有16篇文章符合本研究的条件。基于偏倚风险分析，这些文章的偏倚风险较低。大多数体内研究（16篇中的13篇）表明，ApoA-I MPs显著减少动脉粥样硬化斑块形成。一般来说，ApoA-I MPs在调节HDL代谢（HDL重塑过程、增加胆固醇流出和刺激RCT途径）和抗炎方面发挥重要作用。ApoA-I MPs根据肽序列和给药途径，在减少动脉粥样硬化斑块的能力上可能有所不同。
ApoA-I MPs可通过RCT途径增加胆固醇流出，从而减少小鼠动脉粥样硬化斑块的形成。需要进一步研究以支持将ApoA-I MPs开发为人类动脉粥样硬化的新疗法。
